Treatment plan for children with acute lymphoblastic leukemia, observed
Observes new treatment guidelines in children under 18 with acute lymphoblastic leukemia.
Key facts
- Who runs it
- French Africa Pediatric Oncology Group
- Where
- Conakry, GuineaSee the siteAlso in 2 other countries, 2 sites
- Trial code
- Registry title
- Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 15 Nov 2021
- Expected to end
- 31 Dec 2030
- Type of study
- Observational
- Record updated
- 2 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people from birth to 18 years old who have just been diagnosed with acute lymphoblastic leukemia (ALL) and have not had chemotherapy.
- Age
- 0 to 18 years
- Sex
- All sexes
- Disease stage
- First diagnosis of ALL. Cell type FAB L1 or L2 on cell examination (cytology).
- Earlier treatment
- No earlier chemotherapy.
Main reasons for not taking part
- ALL type L3 (Burkitt)
- ALL that was already treated with chemotherapy
- Trisomy 21 (Down syndrome)
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2
- -
Who cannot take part
- ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21
Where in Guinea
Also in 2 other countries, 2 sites
- CHU Donka 030 BP 554Conakry, GuineaContact: Dr Aïssata BARRY, DRTaking people
About the trial
What the trial wants to find out
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
- Plain-language title
- Treatment plan for children with acute lymphoblastic leukemia, observedGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 March 2026